


PHARMACEUTICAL 2022

Lantern Pharma Inc. Rank 81 of 475





PHARMACEUTICAL 2022



Lantern Pharma Inc. Rank 81 of 475

The relative strengths and weaknesses of Lantern Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 217% points. The greatest weakness of Lantern Pharma Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 351% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	72,716
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,326
Liabilities, Non-Current	53
Other Assets	1,204
Other Compr. Net Income	0
Other Expenses	12,592
Other Liabilities	0
Other Net Income	228
Property and Equipment	30
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	73,950
Liabilities	2,379
Expenses	12,592
Stockholders Equity	71,571
Net Income	-12,363
Comprehensive Net Income	-12,363
Economic Capital Ratio	75%